<DOC>
	<DOCNO>NCT01853319</DOCNO>
	<brief_summary>This open-label phase III study regorafenib patient metastatic colorectal cancer ( mCRC ) progress approved standard therapy . The purpose study provide additional information safety profile Regorafenib .</brief_summary>
	<brief_title>Regorafenib Subjects With Metastatic Colorectal Cancer ( mCRC ) Who Have Progressed After Standard Therapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Male female subject &gt; /= 18 year age Life expectancy least 3 month Histological cytological documentation adenocarcinoma colon rectum Subjects metastatic colorectal cancer ( Stage IV ) Progression within 3 month follow last administration approve standard therapy must include fluoropyrimidine , oxaliplatin , irinotecan , bevacizumab cetuximab/panitumumab KRAS WT ( WT : wildtype i.e . KRAS mutation ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; /= 1 Adequate bone marrow , liver renal function assess follow laboratory requirement Women childbearing potential men must agree use adequate contraception since sign inform consent ( IC ) form least 3 month last study drug administration Prior treatment regorafenib Major surgical procedure , open biopsy , significant traumatic injury within 28 day start study drug Pregnant breastfeeding subject Congestive heart failure &gt; /= New York Heart Association ( NYHA ) class 2 Myocardial infarction le 6 month start study drug Ongoing infection &gt; Grade 2 Common Terminology Criteria Adverse Events ( CTCAE ) v. 4.0 Renal failure require hemoor peritoneal dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>Metastatic colorectal cancer</keyword>
</DOC>